Movement Disorders Clinical Trial
Official title:
Study on the Effect Mechanism of Programmed Flexor-extensor Alternating Electrical Acupiont Stimulation on Upper Limb Functional Reconstruction After Stroke: Study Protocol for a Randomized Controlled Trail
Verified date | March 2023 |
Source | Heilongjiang University of Chinese Medicine |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to study the effect mechanism of programmed flexor-extensor alternating electrical acupiont stimulation on upper limb functional reconstruction after stroke.
Status | Completed |
Enrollment | 84 |
Est. completion date | February 1, 2023 |
Est. primary completion date | April 18, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 35 Years to 75 Years |
Eligibility | Inclusion Criteria: - Inclusion criteria for patients 1. Meet the diagnostic criteria of stroke; 2. Age: 35 ~75 years old, male and female; 3. Course of disease: 2 weeks to 3 months after stroke, stable vital signs, basically normal cognitive function, can cooperate to complete the test; 4. Manual muscle test (MMT) =2, modified Ashworth (MAS) of paralyzed upper limbs was graded ?~?; 5. BMI =28; 6. No serious heart, lung, kidney and other functional damage and serious underlying diseases, no pain in the affected side of the upper limb joint; 7. The informed consent was signed by the patient and/or his/her family members. Note: Patients who meet the above 7 criteria can be included in this study. - Inclusion criteria for healthy subjects: 1. Those who have been proved to be healthy by physical examination and have no organic lesions or obvious functional diseases; 2. Age: 35 ~75 years old, male and female; 3. No cold, fever, cough, headache and other physical abnormalities during the test; 4. Did not take any excitatory drugs in the past one month, no recent treatment related to experimental content; 5. No history of mental or nervous system; 6. The subject agrees and signs the informed consent. - Exclusion Criteria: 1. Severe cognitive dysfunction, severe aphasia, can not cooperate with the whole treatment or testing process; 2. Patients with serious primary diseases such as heart, lung, kidney, liver and endocrine system; 3. Neurological or musculoskeletal diseases affecting functional recovery before onset; 4. Cerebral stem stroke or bilateral stroke; 5. Patients with severe anxiety, depression, affective disorders, schizophrenia and other serious mental disorders; 6. Examination confirmed by brain tumor, brain trauma, brain parasitic diseases, metabolic disorders, rheumatic heart disease, coronary heart disease and other heart disease with atrial fibrillation caused by cerebral embolism; 7. Patients with skin damage, infection or deformity at the treatment site. |
Country | Name | City | State |
---|---|---|---|
China | The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine | Harbin | Heilongjiang |
Lead Sponsor | Collaborator |
---|---|
Yang Liu |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | EEG data of healthy controls | To record the immediate Alpha, Beta, Delta and Theta bands of the eyes-closed resting state EEG of the healthy controls in a quiet without any interference laboratory. | 1 week before the beginning of the whole clinical trail | |
Other | sEMG data of healthy controls | Ask them to do the "reaching and retriving" gross movement, recording the real-time sEMG parameters (RMS and MF) of biceps brachii and triceps brachii muscles during the whole process of the motion. Computer software calculates iEMG and MPF values. | 1 week before the beginning of the whole clinical trail | |
Other | EEG power spectrum analysis of healthy controls | EEG power spectrum analysis is made to evaluate the brain energy state, for better interpreting the movement control strategy of the central nervous system, providing a reference for the prognosis of patients and the curative effect evaluation. | 1 week before the beginning of the whole clinical trail | |
Other | sEMG synergy-coherence analysis of healthy controls | sEMG synergy-coherence analysis is made to evaluate the degree of muscle coordination, for better interpreting the movement control strategy of the central nervous system, providing a reference for the prognosis of patients and the curative effect evaluation. | 1 week before the beginning of the whole clinical trail | |
Primary | EEG data record | To record the immediate Alpha, Beta, Delta and Theta bands of the eyes-closed resting state EEG of patients in the two groups 2 hours before the first treatment.
The EmotivEpoc wireless portable EEG device (developed by Neurotechnology Company, USA) is used to collect EEG data. |
2 hours before the first treatment | |
Primary | EEG data record | To record the immediate Alpha, Beta, Delta and Theta bands of the eyes-closed resting state EEG of patients in the two groups 2 hours after the first treatment.
The EmotivEpoc wireless portable EEG device (developed by Neurotechnology Company, USA) is used to collect EEG data. |
2 hours after the first treatment | |
Primary | EEG data record | To record the immediate Alpha, Beta, Delta and Theta bands of the eyes-closed resting state EEG of patients in the two groups 2 hours before the last treatment.
The EmotivEpoc wireless portable EEG device (developed by Neurotechnology Company, USA) is used to collect EEG data. |
2 hours before the last treatment | |
Primary | EEG data record | To record the immediate Alpha, Beta, Delta and Theta bands of the eyes-closed resting state EEG of patients in the two groups 2 hours after the last treatment.
The EmotivEpoc wireless portable EEG device (developed by Neurotechnology Company, USA) is used to collect EEG data. |
2 hours after the last treatment | |
Primary | EEG power spectrum analysis | EEG power spectrum analysis: EEG data of the four time points as above are preprocessed on the MATLAB platform. And the analysis is used to objectively evaluate the immediate and cumulative effects of different treatment therapies on cerebral cortex activity by Alpha, Beta, Delta and Theta frequency bands. | 1 week after all the EEG data is collected | |
Primary | sEMG data record | Ask the patients to do the "reaching and retriving" gross movement, recording the real-time sEMG data of RMS (root mean square) and MF (median frequency) 1 hour before the first treatment.
sEMG cosynergive-coherence analysis: The signals are collected with the sEMG device (H4A2L8), developed by ThoughtTechnology Ltd, Canada. Datas are respectively collected of the biceps brachii and triceps brachii muscles during the whole process of the motion. Computer software calculates iEMG (integral electromyogram) and MPF (mean power frequency) values. |
1 hour before the first treatment | |
Primary | sEMG data record | Ask the patients to do the "reaching and retriving" gross movement, recording the real-time sEMG data of RMS and MF 1 hour after the first treatment.
sEMG cosynergive-coherence analysis: The signals are collected with the sEMG device (H4A2L8), developed by ThoughtTechnology Ltd, Canada. Datas are respectively collected of the biceps brachii and triceps brachii muscles during the whole process of the motion. Computer software calculates iEMG and MPF values. |
1 hour after the first treatment | |
Primary | sEMG data record | Ask the patients to do the "reaching and retriving" gross movement, recording the real-time sEMG data of RMS and MF 1 hour before the last treatment.
sEMG cosynergive-coherence analysis: The signals are collected with the sEMG device (H4A2L8), developed by ThoughtTechnology Ltd, Canada. Datas are respectively collected of the biceps brachii and triceps brachii muscles during the whole process of the motion. Computer software calculates iEMG and MPF values. |
1 hour before the last treatment | |
Primary | sEMG data record | Ask the patients to do the "reaching and retriving" gross movement, recording the real-time sEMG data of RMS and MF 1 hour after the last treatment.
sEMG cosynergive-coherence analysis: The signals are collected with the sEMG device (H4A2L8), developed by ThoughtTechnology Ltd, Canada. Datas are respectively collected of the biceps brachii and triceps brachii muscles during the whole process of the motion. Computer software calculates iEMG and MPF values. |
1 hour after the last treatment | |
Primary | sEMG coherence analysis | sEMG coherence analysis: Local mean decomposition (LMD) de-noising methods and non-negative matrix decomposition algorithm are used and cosynergive-coherence analysis of the muscle pairs participating in the programmed motion is analyzed, to study the effects of different electrical stimulation methods on the motor coordination and the central control mechanism. | 1 week after all the sEMG data is collected | |
Secondary | Scale evaluation--MBI | MBI (Modified Barthel Index): A daily functional activity assessment. Normal (100 points). Each activity is rated on a scale of 5 (5 points), with a minimum of 1 (full dependence) and a maximum of 5 (full independence). The higher the level, the more independent the activity is.
MBI score of upper limb is evaluated and SPSS26.0 statistical software is used for analysis. A two-sided test is used in this study, and the significance level is p<0.05. Parametric method is used when data conditions meet parametric conditions; non-parametric method is used when data conditions do not meet time parameter conditions. |
3 hours before the whole clinical trail | |
Secondary | Scale evaluation--MBI | The same as above. | 3 hours after the whole clinical trail | |
Secondary | Scale evaluation--CSS | CSS (China Stroke Scale): A neurological deficits assessment. Normal (45 points), Upper limb normal (12 points). Each activity of upper limb is rated on a scale of 7 (0~6 points). The lower the score, the better the situation is.
CSS score of upper limb is evaluated and SPSS26.0 statistical software is used for analysis. A two-sided test is used in this study, and the significance level is P<0.05. Parametric method is used when data conditions meet parametric conditions; non-parametric method is used when data conditions do not meet time parameter conditions. |
3 hours before the whole clinical trail | |
Secondary | Scale evaluation--CSS | The same as above. | 3 hours after the whole clinical trail | |
Secondary | Scale evaluation--FMA | FMA (Fugl-Meyer Assessment): A motor function assessment. Normal (226 points), Upper limb normal (66 points, 33 items). The high the score, the better the situation is.
FMA scale of upper limb is evaluated and SPSS26.0 statistical software is used for analysis. A two-sided test is used in this study, and the significance level is P<0.05. Parametric method is used when data conditions meet parametric conditions; non-parametric method is used when data conditions do not meet time parameter conditions. |
3 hours before the whole clinical trail | |
Secondary | Scale evaluation--FMA | The same as above. | 3 hours after the whole clinical trail | |
Secondary | Scale evaluation--MMT | MMT (Manual Muscle Testing): A muscle strength assessment. Normal (level 5) with a minimum of 0 (no muscle contraction) and a maximum of 5 (normal, can resist gravity and sufficient resistance). The higher the score, the more normal muscle strength tends to be.
FMA scale of upper limb is evaluated and SPSS26.0 statistical software is used for analysis. A two-sided test is used in this study, and the significance level is P<0.05. Parametric method is used when data conditions meet parametric conditions; non-parametric method is used when data conditions do not meet time parameter conditions. |
3 hours before the whole clinical trail | |
Secondary | Scale evaluation--MMT | The same as above. | 3 hours after the whole clinical trail | |
Secondary | Scale evaluation--Brunnstrom | Brunnstrom motor function assessment: A limb function recovery assessment. Normal (level 6) with a minimum of 1 (no movement) and a maximum of 6 (basiclly normal). The higher the level, the better recovery is.
Brunnstrom scale of upper limb is evaluated and SPSS26.0 statistical software is used for analysis. A two-sided test is used in this study, and the significance level is P<0.05. Parametric method is used when data conditions meet parametric conditions; non-parametric method is used when data conditions do not meet time parameter conditions. |
3 hours before the whole clinical trail | |
Secondary | Scale evaluation--Brunnstrom | The same as above. | 3 hours after the whole clinical trail |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05623644 -
Multimodal MR Imaging Study on ET and PD Patients Subjected With MRgFUS Thalamotomy
|
||
Active, not recruiting |
NCT03548779 -
North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2
|
N/A | |
Completed |
NCT03295786 -
Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease
|
Phase 1/Phase 2 | |
Completed |
NCT03722212 -
Early Diagnosis of the GLUT1 Deficiency Syndrome With a Blood Based Test
|
N/A | |
Recruiting |
NCT05973929 -
Movement Disorders in Multiple Sclerosis Patients
|
||
Terminated |
NCT02823158 -
Bilateral Pallidal Stimulation in Patients With Advanced Parkinson's Disease-LATESTIM
|
N/A | |
Enrolling by invitation |
NCT01210781 -
Target Planning for Placement of DBS-electrodes and Follow-up of the Clinical Efficacy of Stimulation
|
||
Enrolling by invitation |
NCT00355927 -
Sedation During Microelectrode Recordings Before Deep Brain Stimulation for Movement Disorders.
|
N/A | |
Completed |
NCT00037167 -
Effects of Exercise Poles on Older Adults During Exercise Walking
|
Phase 1/Phase 2 | |
Recruiting |
NCT04784494 -
MST for Parkinson's Disease
|
N/A | |
Terminated |
NCT03270189 -
Effect of the Visual Information Change in Functional Dystonia
|
N/A | |
Recruiting |
NCT04176692 -
The Effects of Muscle Characteristics on the Control of Shoulder Complex During Functional Movements
|
||
Recruiting |
NCT04061135 -
Neurophysiological, Behavioral, and Cognitive Networks in Movement Disorders
|
N/A | |
Suspended |
NCT04912115 -
Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia
|
Phase 2 | |
Completed |
NCT00500994 -
Neurobiology of Functional Movement Disorder and Non-Epileptic Seizures
|
Early Phase 1 | |
Completed |
NCT04536987 -
Robot Therapy for Rehabilitation of Hand Movement After Stroke
|
Phase 2 | |
Recruiting |
NCT00001208 -
Botulinum Toxin for the Treatment of Involuntary Movement Disorders
|
||
Completed |
NCT02392078 -
Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System
|
||
Completed |
NCT00552474 -
Deep Brain Stimulation to Treat Symptoms of Parkinson's Disease
|
N/A | |
Not yet recruiting |
NCT05032911 -
Sensorimotor Control in People With and Without Neck Pain
|